N-octanoyl dopamine is superior to dopamine in protecting graft contractile function when administered to the heart transplant recipients from brain-dead donors

Publication date: Available online 16 October 2019Source: Pharmacological ResearchAuthor(s): Sivakkanan Loganathan, Yuxing Guo, Weipeng Jiang, Tamás Radovits, Mihály Ruppert, Alex Ali Sayour, Maik Brune, Paige Brlecic, Phillipp Gude, Adrian-Iustin Georgevici, Benito Yard, Matthias Karck, Sevil Korkmaz-Icöz, Gábor SzabóAbstractThe major source of heart transplantation comes from brain-dead (BD) donors. However, brain death and myocardial ischemia/reperfusion injury during transplantation may lead to cardiac dysfunction and hemodynamic instability. A previous work demonstrated that pre-treatment of BD donors with dopamine improved the graft survival of heart allograft in recipient after transplantation. However, low-dose dopamine treatment might result in tachycardia and hypertension. Our previous experimental study showed that pre-treatment of BD donor rats with the dopamine derivate N-octanoyl dopamine (NOD), devoid of any hemodynamic effects, improved graft function after transplantation. Herein, we hypothesized that NOD confers superior myocardial protection and improves graft function than dopamine, when administered to the heart transplant recipients from BD donors. Male Lewis donor rats were either subjected to sham-operation or brain death via a subdurally placed balloon followed by 5.5 h monitoring. Then, the hearts were explanted and heterotopically transplanted into Lewis recipient rats. Shortly before the onset of reperfusion,...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research

Related Links:

Hypertension (HTN) is common after orthotopic heart transplant (OHT) and is associated with cardiac allograft vasculopathy (CAV), which is strongly related to mortality. Few data are available regarding whether anti-HTN medications in OHT patients who develop HTN will reduce mortality or incidence of CAV. Our goal was to determine if specific anti-HTN medications were associated with a reduction in CAV or were associated with survival.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 451 Source Type: research
ConclusionDLT followed by percutaneous ASD closure is an efficient therapeutic approach in patients with end-stage ASD associated PAH that may offer an alternative option to HLT.
Source: Archives of Cardiovascular Diseases Supplements - Category: Cardiology Source Type: research
Cardiac allograft vasculopathy (CAV) is a highly prevalent vaso-occlusive disease that is a leading cause of graft failure and mortality after heart transplantation. While the pathogenesis of CAV remains incompletely understood, histologic evidence suggests that macrophages, which constitute an important part of the innate immune response, may play an important role. Prior studies in pulmonary hypertension have shown that macrophage-derived leukotriene B4 (LTB4) induces proliferation and hypertrophy of human pulmonary artery smooth muscle cells.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 218 Source Type: research
Despite improvements in overall graft function and patient survival rates after solid organ transplantation, complications can lead to significant morbidity and mortality. Cardiovascular complications include heart failure, arrhythmias leading to sudden death, hypertension, left ventricular hypertrophy, and allograft vasculopathy in heart transplantation. Neurologic complications include stroke, posterior reversible encephalopathy syndrome, infections, neuromuscular disease, seizure disorders, and neoplastic disease. Acute kidney injury occurs from immunosuppression with calcineurin inhibitors or as a result of graft failu...
Source: Critical Care Clinics - Category: Intensive Care Authors: Source Type: research
Authors: Peled Y, Freimark D, Har-Zahav Y, Nachum E, Kogan A, Kassif Y, Lavee J Abstract BACKGROUND: Heart transplantation (HT) is the treatment of choice for patients with end-stage heart failure. The HT unit at the Sheba Medical Center is the largest of its kind in Israel. OBJECTIVES: To evaluate the experience of HT at a single center, assess trends over 3 decades, and correlate with worldwide data. METHODS: Between 1990 and 2017, we reviewed all 285  adult HT patients. Patients were grouped by year of HT: 1990-1999 (decade 1), 2000-2009 (decade 2), and 2010-2017 (decade 3). RESULTS: The percent...
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
ConclusionsPatients with CS have similar post-transplant hemodynamics as patients without CS, without evidence of right ventricular dysfunction or pulmonary hypertension. Neither significant rejection nor recurrence of sarcoid in the allograft was observed in this cohort of patients with CS. Survival is similar between patients with CS and those without CS. Heart transplant is a viable strategy in selected patients with CS with excellent outcomes.RésuméIntroductionLa transplantation cardiaque orthotopique (TCO) est de plus en plus utilisée lors d’insuffisance cardiaque terminale liée &agra...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions CS patients have similar post-transplant hemodynamics as non-CS patients, without evidence of RV dysfunction or pulmonary hypertension. No significant rejection nor recurrence of sarcoid in the allograft were observed in this cohort of patients with CS. Survival is similar between CS and non-CS patients. Heart transplant is a viable strategy in selected CS patients with excellent outcomes. Teaser Orthotopic heart transplant (OHT) is utilized for end-stage heart failure due to cardiac sarcoidosis (CS). There is a lack of data on long-term outcomes. We explored changes in hemodynamics, allograft rejection and sur...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Allograft failure is an important cause of morbidity and mortality in heart transplant recipients. Several reasons for graft dysfunction: hypertension, kidney failure, vasculopathy and allograft hypertrophy, have been attributed to treatment with calcineurin inhibitors. Inhibitors of the mechanistic target of rapamycin (mTOR) may have a more favourable cardiovascular profile. We used data from the randomised, controlled NOCTET trial to assess if treatment with an mTOR-inhibitor attenuates allograft hypertrophy and prevents left ventricular dysfunction.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Cardiac allograft hypertrophy is common after heart transplantation (HTX) and associated with increased long-term mortality. Post-transplant hypertension, kidney failure, vasculopathy and allograft hypertrophy has been attributed to treatment with calcineurin inhibitors. Inhibitors of the mechanistic target of rapamycin (mTOR) may have beneficial effects on cardiac function and reduce left ventricular mass (LVM) in HTX. However, the effect of mTOR inhibitors on LVM remains unknown in de novo HTX.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
More News: Bone Graft | Brain | Cardiology | Drugs & Pharmacology | Heart | Heart Transplant | Hypertension | Neurology | Study | Transplant Surgery | Transplants